Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Intravesical FL115 Alone or in Combination With BCG in Subjects With Non-Muscle Invasive Bladder Cancer, Including Dose Escalation and Cohort Expansion

NCT07122414 is registered in ClinicalTrials.gov with Suzhou Forlong Biotechnology Co., Ltd as lead sponsor.

NCT NCT07122414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07122414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Intravesical FL115 Alone or in Combination With BCG in Subjects With Non-Muscle Invasive Bladder Cancer, Including Dose Escalation and Cohort Expansion
Lead sponsor
Suzhou Forlong Biotechnology Co., Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 16, 2024
Completion date
October 10, 2028
Enrollment
80 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle invasive bladder cancer (nmibc)